EP3164155 - TREPROSTINIL FORMULATIONS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 16.12.2022 Database last updated on 22.08.2024 | |
Former | The patent has been granted Status updated on 07.01.2022 | ||
Former | Grant of patent is intended Status updated on 26.09.2021 | ||
Former | Examination is in progress Status updated on 08.11.2019 | ||
Former | Request for examination was made Status updated on 07.04.2017 | ||
Former | The international publication has been made Status updated on 13.01.2017 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states United Therapeutics Corporation 1040 Spring Street Silver Spring, MD 20910 / US | [2017/19] | Inventor(s) | 01 /
PHARES, Ken 7005 Bowater Crossing Hillborough, North Carolina 27278 / US | 02 /
CHANG, Courtney 9205 Giralda Walk Raleigh, North Carolina 27617 / US | [2017/19] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2017/19] | Application number, filing date | 15731463.4 | 12.06.2015 | [2017/19] | WO2015US35595 | Priority number, date | US201462011689P | 13.06.2014 Original published format: US 201462011689 P | [2017/19] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015192030 | Date: | 17.12.2015 | Language: | EN | [2015/50] | Type: | A1 Application with search report | No.: | EP3164155 | Date: | 10.05.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.12.2015 takes the place of the publication of the European patent application. | [2017/19] | Type: | B1 Patent specification | No.: | EP3164155 | Date: | 09.02.2022 | Language: | EN | [2022/06] | Search report(s) | International search report - published on: | EP | 17.12.2015 | Classification | IPC: | A61K47/32, A61K9/14, A61K31/557, A61K9/10, A61P9/12 | [2021/39] | CPC: |
A61K31/192 (EP,CN,KR,US);
A61K45/06 (EP,CN,KR,US);
A61K31/785 (EP,CN,KR,US);
A61K47/32 (EP,CN,KR,US);
A61K47/585 (EP,KR,US);
A61K9/0053 (KR,US);
A61K9/10 (EP,CN,KR,US);
A61K9/20 (KR,US);
A61K9/48 (KR,US);
A61P11/00 (EP,KR);
A61P43/00 (EP,KR);
A61P9/10 (EP,KR);
| C-Set: |
A61K31/192, A61K2300/00 (EP,CN,US);
A61K31/785, A61K2300/00 (US,CN,EP) |
Former IPC [2017/20] | A61K47/32, A61K9/10, A61K31/557, A61K9/14 | ||
Former IPC [2017/19] | A61K47/32, A61K9/10, A61K31/557 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/19] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | TREPROSTINILFORMULIERUNGEN | [2017/19] | English: | TREPROSTINIL FORMULATIONS | [2017/19] | French: | FORMULATIONS DE TRÉPROSTINIL | [2017/19] | Entry into regional phase | 12.01.2017 | National basic fee paid | 12.01.2017 | Designation fee(s) paid | 12.01.2017 | Examination fee paid | Examination procedure | 12.01.2017 | Examination requested [2017/19] | 12.01.2017 | Date on which the examining division has become responsible | 27.07.2017 | Amendment by applicant (claims and/or description) | 13.11.2019 | Despatch of a communication from the examining division (Time limit: M06) | 12.05.2020 | Reply to a communication from the examining division | 27.09.2021 | Communication of intention to grant the patent | 29.12.2021 | Fee for grant paid | 29.12.2021 | Fee for publishing/printing paid | 29.12.2021 | Receipt of the translation of the claim(s) | Opposition(s) | 10.11.2022 | No opposition filed within time limit [2023/03] | Fees paid | Renewal fee | 16.06.2017 | Renewal fee patent year 03 | 12.06.2018 | Renewal fee patent year 04 | 13.06.2019 | Renewal fee patent year 05 | 15.06.2020 | Renewal fee patent year 06 | 14.06.2021 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 12.06.2015 | AL | 09.02.2022 | AT | 09.02.2022 | CY | 09.02.2022 | CZ | 09.02.2022 | DK | 09.02.2022 | EE | 09.02.2022 | FI | 09.02.2022 | HR | 09.02.2022 | LT | 09.02.2022 | LV | 09.02.2022 | MC | 09.02.2022 | MK | 09.02.2022 | NL | 09.02.2022 | PL | 09.02.2022 | RO | 09.02.2022 | RS | 09.02.2022 | SE | 09.02.2022 | SI | 09.02.2022 | SK | 09.02.2022 | SM | 09.02.2022 | BG | 09.05.2022 | NO | 09.05.2022 | GR | 10.05.2022 | IS | 09.06.2022 | PT | 09.06.2022 | IE | 12.06.2022 | LU | 12.06.2022 | BE | 30.06.2022 | CH | 30.06.2022 | LI | 30.06.2022 | [2024/22] |
Former [2024/20] | HU | 12.06.2015 | |
AL | 09.02.2022 | ||
AT | 09.02.2022 | ||
CY | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SI | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
IE | 12.06.2022 | ||
LU | 12.06.2022 | ||
BE | 30.06.2022 | ||
CH | 30.06.2022 | ||
LI | 30.06.2022 | ||
Former [2024/18] | HU | 12.06.2015 | |
AL | 09.02.2022 | ||
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SI | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
IE | 12.06.2022 | ||
LU | 12.06.2022 | ||
BE | 30.06.2022 | ||
CH | 30.06.2022 | ||
LI | 30.06.2022 | ||
Former [2023/25] | AL | 09.02.2022 | |
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SI | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
IE | 12.06.2022 | ||
LU | 12.06.2022 | ||
BE | 30.06.2022 | ||
CH | 30.06.2022 | ||
LI | 30.06.2022 | ||
Former [2023/21] | AL | 09.02.2022 | |
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SI | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
IE | 12.06.2022 | ||
LU | 12.06.2022 | ||
CH | 30.06.2022 | ||
LI | 30.06.2022 | ||
Former [2023/20] | AL | 09.02.2022 | |
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SI | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
IE | 12.06.2022 | ||
Former [2023/10] | AL | 09.02.2022 | |
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SI | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2023/08] | AL | 09.02.2022 | |
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
MC | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2023/01] | AL | 09.02.2022 | |
AT | 09.02.2022 | ||
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2022/49] | AT | 09.02.2022 | |
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SK | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2022/48] | AT | 09.02.2022 | |
CZ | 09.02.2022 | ||
DK | 09.02.2022 | ||
EE | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2022/47] | AT | 09.02.2022 | |
DK | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RO | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
SM | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2022/46] | AT | 09.02.2022 | |
DK | 09.02.2022 | ||
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2022/42] | AT | 09.02.2022 | |
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
IS | 09.06.2022 | ||
PT | 09.06.2022 | ||
Former [2022/39] | AT | 09.02.2022 | |
FI | 09.02.2022 | ||
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
PT | 09.06.2022 | ||
Former [2022/36] | AT | 09.02.2022 | |
HR | 09.02.2022 | ||
LT | 09.02.2022 | ||
LV | 09.02.2022 | ||
NL | 09.02.2022 | ||
PL | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
GR | 10.05.2022 | ||
PT | 09.06.2022 | ||
Former [2022/35] | HR | 09.02.2022 | |
LT | 09.02.2022 | ||
NL | 09.02.2022 | ||
RS | 09.02.2022 | ||
SE | 09.02.2022 | ||
BG | 09.05.2022 | ||
NO | 09.05.2022 | ||
PT | 09.06.2022 | ||
Former [2022/34] | LT | 09.02.2022 | |
NL | 09.02.2022 | ||
NO | 09.05.2022 | ||
PT | 09.06.2022 | ||
Former [2022/33] | LT | 09.02.2022 | |
NO | 09.05.2022 | Cited in | International search | [Y]WO2009048606 (FUISZ RICHARD C [US]); | [Y]WO2009137066 (UNITED THERAPEUTICS CORP [US], et al); | [Y]WO2009158010 (CONCERT PHARMACEUTICALS INC [US], et al); | by applicant | US4093657 | US4185088 | US4306075 | US4593073 | US5091175 | US5153222 | US5234953 | US5491397 | US5607669 | US5679717 | US5693675 | US5917007 | US5919832 | US5929184 | US6054486 | US6066678 | WO0057701 | US6129910 | US6190649 | US6203785 | US6271264 | US6294163 | US6433026 | US6441245 | US6517825 | US6521212 | US6528688 | US2003099711 | US6610283 | US6700025 | US6756117 | US6756033 | US2004151687 | US6784254 | US6803386 | US6809223 | US2005165111 | US7101916 | US7125547 | US7199157 | US2007098678 | US2007122375 | US7229613 | US2007190021 | US7384978 | US2008200449 | US7417070 | US2008261942 | US2008280986 | US2009036465 | US2009124697 | US2010076083 | US2010179235 | US7879909 | US2011152204 | US7999007 | WO2012009816 | US2012190888 | US8232316 | US2012197041 | US8242305 | US8252839 | US2012216801 | US8350079 | US8349892 | US2013022570 | US8410169 | US8461393 | US8481782 | US2013189215 | US8497393 | US8536363 | US2013261187 | US8563614 | US8597684 | US8609728 | US8653137 | US8658694 | US8748657 | US8747897 | US2014275262 | US2014275616 | US2014288314 | US8940930 | US8969409 |